Logo

IMMX

Immix Biopharma, Inc.

IMMX

Immix Biopharma, Inc. • NASDAQ
$4.25 ▼ -1.16% (-0.05)
Market Cap $142.69 M
52w High $4.60
52w Low $1.34
Dividend Yield 0%
P/E -5.52
Volume 72.14K
Outstanding Shares 33.57M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $7.663M ▲ $-7.586M ▼ 0% $-0.24 ▼ $-7.481M ▼
Q2-2025 $0 $6.718M ▲ $-6.623M ▼ 0% $-0.22 ▼ $-6.638M ▼
Q1-2025 $0 $4.683M ▼ $-4.543M ▲ 0% $-0.15 ▲ $-4.624M ▲
Q4-2024 $0 $4.987M ▼ $-4.812M ▲ 0% $-0.17 ▲ $-4.946M ▲
Q3-2024 $0 $7.395M $-7.149M 0% $-0.24 $-7.369M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $15.947M ▲ $20.081M ▲ $11.816M ▲ $8.265M ▲
Q2-2025 $11.638M ▼ $15.635M ▼ $10.982M ▲ $4.653M ▼
Q1-2025 $15.921M ▼ $19.892M ▼ $10.298M ▲ $9.594M ▼
Q4-2024 $17.682M ▼ $22.948M ▼ $9.697M ▲ $13.251M ▼
Q3-2024 $19.69M $25.142M $7.591M $17.551M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.586M ▼ $-5.906M ▼ $-372.456K ▼ $10.608M ▲ $4.309M ▲ $-6.278M ▼
Q2-2025 $-6.623M ▼ $-5.31M ▼ $-127.63K ▼ $1.11M ▲ $-4.283M ▼ $-5.437M ▼
Q1-2025 $-4.543M ▲ $-1.685M ▼ $-67.713K ▲ $0 $-1.761M ▲ $-1.753M ▲
Q4-2024 $-4.812M ▲ $-1.476M ▲ $-507.151K ▼ $0 $-2.008M ▲ $-1.983M ▲
Q3-2024 $-7.149M $-4.036M $-271.542K $0 $-4.285M $-4.308M

Five-Year Company Overview

Income Statement

Income Statement Immix Biopharma is still a clinical‑stage company with essentially no product revenue. Its income statement is driven almost entirely by research, development, and overhead costs. Losses have been steady but relatively small in absolute terms, reflecting a lean cost base rather than large-scale operations. Per‑share losses have moved around over the last few years, which is typical for a young biotech as trial activity, headcount, and financing costs rise and fall. The key point: this is a pre-commercial R&D story, not yet a revenue or earnings story.

Balance Sheet

Balance Sheet The balance sheet is simple and light. Assets are mostly cash, with no reported debt, which reduces financial strain but also highlights dependence on future fund-raising. Equity is modest and has fluctuated as losses accumulate and new capital is raised. Overall, this looks like a small company with a clean but thin balance sheet: cash on hand, no leverage, and limited tangible resources beyond its intellectual property and clinical programs.

Cash Flow

Cash Flow Cash flow is negative from operations, as expected for a company funding clinical trials without product sales. Free cash flow is also negative, driven by ongoing research spending rather than heavy investment in physical assets. There is essentially no meaningful capital expenditure, reinforcing that most cash goes directly into people, trials, and platform development. The company’s ability to keep funding this burn will depend on its access to capital markets and potential partnerships over time.

Competitive Edge

Competitive Edge Immix is trying to carve out a position in high‑need, niche disease areas where there are few or no approved treatments, particularly AL amyloidosis and certain tumors. Its main competitive angles are: a CAR‑T program claiming a gentler safety profile than many existing cell therapies, a tumor‑targeting platform that hits multiple parts of the tumor environment, and several favorable regulatory designations that can speed review and extend exclusivity. At the same time, it is a small player in a field crowded with large pharma and advanced cell and gene therapy companies, so execution, clinical data quality, and partnerships will be critical to sustaining any advantage.

Innovation and R&D

Innovation and R&D Innovation and R&D are the heart of the company. Immix is built around two platforms: one that delivers combination cancer drugs deep into tumors, and another that designs CAR‑T cell therapies to be more tolerable and potentially usable outside intensive hospital settings. The lead asset, NXC‑201, targets difficult blood disorders and may expand into autoimmune diseases if data support it. Another asset, IMX‑110, addresses solid tumors via the tumor micro‑environment. The company has secured multiple special regulatory statuses, which can be powerful if the clinical results continue to look strong. However, all of this remains in the clinical trial phase, so the scientific promise still needs to translate into confirmatory data, approvals, and real‑world use.

Summary

Immix Biopharma is an early‑stage oncology and rare‑disease biotech with no commercial revenue yet and a straightforward, cash‑driven financial profile: ongoing losses, negative operating cash flow, and no debt, funded by external capital. The story is almost entirely about its science and pipeline, especially the NXC‑201 CAR‑T program, which aims to pair strong efficacy with a more manageable safety profile in high‑need conditions. Regulatory designations and focus on under‑served diseases offer meaningful potential upside but also come with the usual binary risks of clinical development and financing dependence. In short, this is a small, R&D‑heavy company where future value will be determined far more by trial results, regulatory outcomes, and partnership execution than by current financial statements.

NEWS

November 12, 2025 · 8:45 AM UTC

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Read more

November 3, 2025 · 8:45 AM UTC

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Read more

October 14, 2025 · 8:45 AM UTC

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Read more

October 6, 2025 · 4:05 PM UTC

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Read more

October 1, 2025 · 8:45 AM UTC

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

Read more